Adaptin Bio (APTN) EBITDA (2023 - 2026)

Adaptin Bio (APTN) has 4 years of EBITDA data on file, last reported at -$1.1 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA fell 34.53% year-over-year to -$1.1 million; the trailing twelve-month figure through Mar 2026 stood at -$5.7 million (down 82.93% YoY), and the FY2025 full-year result was -$5.4 million, down 110.71% from the prior year.
• EBITDA improved to -$1.1 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$34155.0 in Q4 2023 to a low of -$1.7 million in Q3 2025.
• A 4-year average of -$836915.8 and a median of -$850458.0 in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA tumbled 2216.71% in 2024 and tumbled 34.53% in 2026, its largest moves.
• Tracing APTN's EBITDA over 4 years: stood at -$34155.0 in 2023, then tumbled by 1387.57% to -$508080.0 in 2024, then tumbled by 169.25% to -$1.4 million in 2025, then advanced by 16.36% to -$1.1 million in 2026.
• Business Quant data shows APTN's EBITDA at -$1.1 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.7 million in Q3 2025.